Chronic lung diseases pose a tremendous global burden. At least one in four people suffer
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …

Introduction: Mesenchymal stromal (stem) cell (MSC) therapies are emerging as a promising
therapeutic intervention in patients with Acute Respiratory Distress Syndrome (ARDS) and …

Macrophages play a key role in the development of sepsis-induced acute respiratory
distress syndrome (ARDS). Recent evidence has proved that glycolysis plays an important …

Antibiotic resistance is creating enormous attention on the development of new antibiotic-
free therapy strategies for bacterial diseases. Mesenchymal stromal stem cells (MSCs) are …

Rationale: Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair
in coronavirus disease (COVID-19)–related acute respiratory distress syndrome (ARDS) …

Acute inflammatory diseases such as acute colitis, kidney injury, liver failure, lung injury,
myocardial infarction, pancreatitis, septic shock, and spinal cord injury are significant causes …

Abstract Background Mesenchymal stromal cells (MSCs) may be of benefit in acute
respiratory distress syndrome (ARDS) due to immunomodulatory, reparative, and …

Abstract Background SARS-CoV-2, which majorly affects the lungs and respiratory tract is
thought due to dysregulation of the immune system which causes an immense imbalance of …

Abstract Coronavirus disease 2019 (COVID-19), a pandemic disease caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV2), is growing at an exponential rate …

Background Mesenchymal stem cell (MSC) derived extracellular vesicles (EVs) have been
proposed as an alternative to cell therapy, creating new possible delivery modalities such as …